Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Alimera Sciences, Inc. (ALIM)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
5.40+0.39 (+7.78%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close5.01
Open5.03
Bid3.40 x 3100
Ask5.95 x 2900
Day's Range4.91 - 5.68
52 Week Range3.94 - 10.50
Volume37,545
Avg. Volume27,133
Market Cap37.816M
Beta (5Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)-0.97
Earnings DateAug 11, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALIM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Alimera Sciences, Inc.
    Daily – Vickers Top Insider Picks for 01/05/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    5 months agoArgus Research
View more
  • GlobeNewswire

    Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes

    Recently presented data further demonstrate steroid challenge is highly predictive of IOP response post-FAc regardless of steroid choiceATLANTA, May 12, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that the phase 4 PALADIN study confirmed the benefit of using a prior course of cort

  • Zacks

    Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates

    Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.87% and 8.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Alimera Sciences Reports First Quarter 2022 Results

    Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021U.S. Net Revenue Increased 23% vs. First Quarter of 2021U.S. End User Demand Up 25% vs. First Quarter of 2021 ATLANTA, May 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter

Advertisement
Advertisement